Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

A Peek Into Latest 13-F Filing: Top Hedge Fund Stocks

Published 05/17/2018, 09:41 PM
Updated 07/09/2023, 06:31 AM

Investors have started mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms.

The group, often known as hedge funds and shifting composition, has outperformed the broad stock market this year after nearly a decade of underperformance. This is especially true as the HFRI Fund Weighted Composite Index gained 0.39% through April against the loss of 0.38% for the S&P 500.

Technology: A Sweet Spot

Hedge Fund “Hot Dogs," which are defined as stocks that capture the maximum hedge-fund dollars, centers around the technology, media and Internet sectors. Topping the list is FANG stocks, acronym for Facebook (NASDAQ:FB) , Amazon (NASDAQ:AMZN) , Netflix (NASDAQ:NFLX) and Alphabet (NASDAQ:GOOGL) , which lost their charm in March, slipping into deep correction territory (down more than 10% from its latest peak). The beaten down prices have compelled big investors to buy more shares of these stocks given their compelling valuation and encouraging fundamentals.

In particular, hedge funds owned $19.4 billion in FB, $12.2 billion in AMZN, $8.5 billion in NFLX and $18.9 billion in GOOGL. Out of these, Amazon has a solid Zacks Rank #2 (Buy) while others have a Zacks Rank #3 (Hold).

The Zacks Ranked #3 software companies like Microsoft (NASDAQ:MSFT) , Adobe Systems (NASDAQ:ADBE) and Electronic Arts (NASDAQ:EA) EA also gained hedge funds love with investments of $16.4 billion, $6.6 billion and $5.5 billion, respectively. Meanwhile, Apple (NASDAQ:AAPL) with a Zacks Rank #3 remains the beloved stock of Warren Buffett’s Berkshire Hathaway (NYSE:BRKa) as it purchased an additional 75 million shares in the iPhone maker in the first quarter, raising its stake to $44 billion or 5%. However, Bloomberg noted that institutional investors abandoned Apple at a rate not seen since 2008. As such, Apple dropped from eight position to the 18th on the list.

The Zacks Ranked #3 Time Warner (NYSE:TWX) is also a hot stock, attracting investments of $10.5 billion from the hedge funds.

Healthcare Gains Love

Besides technology, healthcare is the second top choice of the hedge funds with bets on a insurers like UnitedHealth Group (NYSE:UNH) UNH and Anthem ANTM. The move came due to the steep decline in their share prices after Jeff Bezos, Warren Buffett and Jamie Dimon announced a joint venture to curb medical costs. UNH carries a Zacks Rank #3 while ANTM has a Zacks Rank #2.

The pharmacy benefits managers Express Scripts ESRX and CVS Health Corp (NYSE:CVS) CVS also became friends of hedge fund managers as their stock price tumbled on speculation that Amazon could enter that business. CVS seems a nice option with a Zacks Rank #3.

Small Caps Intact

With small-cap stocks on a tear lately, as evident by the Russell 2000 Index’s new records, many investors might want to invest like billionaires in this space. Although the hedge fund’s small-cap space is dominated by the health care sector, the top two stocks, Green Brick Partners Inc. GRBK and Mammoth Energy Services Inc. TUSK, based on ownership value as a percentage of market cap does not belong to healthcare.

The next are the three health-care companies, namely Genomic Health (NASDAQ:GHDX) , Zogenix (NASDAQ:ZGNX) and Retrophin (NASDAQ:RTRX) that showed that hedge funds had a 48% or greater ownership of the stock as a percentage of market cap. Genomic Health currently carries a top Zacks Rank #1 (Strong Buy) with solid earnings estimate revision of 13 cents over the past 30 days for this year. You can see the complete list of today’s Zacks #1 Rank stocks here.

In particular, hedge funds added exposure to small-cap biotech companies like PTC Therapeutics (NYSE:P) , Pacira Pharmaceuticals (NASDAQ:PCRX) , Strongbridge Biopharma (NASDAQ:SBBP) , and Corium International CORI in the first quarter.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



Time Warner Inc. (TWX): Free Stock Analysis Report

Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Netflix, Inc. (NFLX): Free Stock Analysis Report

Facebook, Inc. (FB): Free Stock Analysis Report

Alphabet Inc. (GOOGL): Free Stock Analysis Report

Apple Inc. (AAPL): Free Stock Analysis Report

Microsoft Corporation (MSFT): Free Stock Analysis Report

Adobe Systems Incorporated (ADBE): Free Stock Analysis Report

Genomic Health, Inc. (GHDX): Free Stock Analysis Report

Retrophin, Inc. (RTRX): Free Stock Analysis Report

Strongbridge Biopharma PLC (SBBP): Free Stock Analysis Report

Zogenix, Inc. (ZGNX): Free Stock Analysis Report

Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report

Pandora Media, Inc. (P): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.